SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language

CARDIOVASCULAR

International | eng
Country Language

Supera™ Stent

Results Matter. Platform Matters.

Supera stent
Stent Design

Platform Matters—Unique Interwoven Design of Supera™ Stent

Breakthrough Technology in Stent Platform

The Supera™ Stent’s unique design results in a platform with features unmatched among standard nitinol peripheral stents:


Strength—its high resistance to compression1

Strength


Low chronic outward force against vessel walls2

Outward force


High flexibility,3 which allows for fracture resistance4

High flexibility

View the Supera™ Stent Difference

The interwoven nitinol design provides high structural integrity and kink resistance, producing the features that set the Supera™ Stent apart.

View the difference

Offering Unparalleled Strength for Compression Resistance

The Supera™ Stent exhibits more than 4 times the compression resistance of all other self-expanding nitinol stents.2 

Laser-cut stent vs. Supera stent

Optimizes luminal gain and maintains circular geometry

Supera Stent

SUPERA™ STENT21

Same artery shown, with a Supera™ Stent distal to the SNS

Supera Stent

SNS21

Exerting the Least Chronic Outward Force on the Vessel Wall2

While laser-cut nitinol stents are designed and required to be oversized for deployment, the Supera™ Stent is unique in that it is sized 1:1 with the vessel diameter. So as seen in the image below, the laser-cut stents inherently exert force on the vessel wall throughout the lifetime of the stent, which in turn can result in endovascular injury over the long term. The lower chronic outward force (COF) with the Supera™ Stent results in fewer vessel injuries.2,4
 

Standard Nitinol Stent (SNS) Designs

Standard Nitinol StentPushes against the vessel to open, through lifetime of SNSsupera chronic tablesupera chronic table
STENT OVERSIZING HIGH COF2VESSEL INJURY4
Chronic outward force (COF) is exerted on vessel by self-expanding stents due to inherent oversizing


Supera™ Stent

Supera Stent1:1 sizing allows to scaffold the vessel to maintain opensupera chronic tablesupera chronic table
SIZING 1:1 LOW COF2MINIMAL VESSEL
INJURY4
Supera™ Stent is sized 1:1 with the prepared vessel and therefore has minimal chronic outward force

Providing Unparalleled Flexibility3 and Zero Fractures4-20

Other self-expanding nitinol stents are fashioned from a rigid, inflexible tube that is laser-cut. As shown in the photo below, due to design and materials properties, some laser cut stents are less likely to conform to a dynamic vascular environment and can potentially kink and fracture in tortuous vessels (left).
 

Laser-Cut Stents

Laser-cut stents

Supera™  Stent

Supera Stent


With the Supera™ Stent, however, individual flexible nitinol wires are interwoven for unparalleled flexibility,3 excellent kink resistance, and the ability to mimic the natural movement of the anatomy1,21,22 (right).

Consequently, data on over 2,000 patients published in 17 studies have shown that at 1 year the Supera™ Stent has zero fractures.4-20
 

0 fractures

REFERENCES

  1. Data on file at Abbott.
  2. Competitors tested include Astron Pulsar-18, Complete SE, EverFlex, Innova, LifeStent, Misago, S.M.A.R.T., and Zilver PTX. Data on file at Abbott.
  3. Flexibility is defined as kink resistance.  Competitors tested include Astron Pulsar-18, Complete SE,  EverFlex, Innova, LifeStent, Misago, S.M.A.R.T., and Zilver PTX. Data on file at Abbott.
  4. Garcia L. et al., Catheterization and Cardiovascular Interventions 2017 Jun 1;89(7):1259-1267.
  5. Brescia AA. et al., J Vasc Surg. 2015 Jun;61(6):1472-8
  6. Chan YC. et al., J Vasc Surg. 2015 Nov;62(5):1201-9.
  7. Dumantepe M. Vasc Endovascular Surg. 2017 Jul;51(5):240-246.
  8. George JC. et al., J Vasc Interv Radiol. 2014 Jun;25(6):954-61.
  9. Goltz JP. et al., J Endovasc Ther. 2012 Jun;19(3):450-6.
  10. León LR Jr. et al., J Vasc Surg. 2013 Apr;57(4):1014-22.
  11. Montero-Baker M. et al., J Vasc Surg. 2016 Oct;64(4):1002-8.
  12. Myint M. et al., J Endovasc Ther. 2016 Jun;23(3):433-41.
  13. Palena LM. et al., J Endovasc Ther. 2018 Oct;25(5):588-591.
  14. Scheinert D. et al., JACC Cardiovasc Interv. 2013 Jan;6(1):65-71.
  15. Scheinert D. et al., J Endovasc Ther. 2011 Dec;18(6):745-52.
  16. Steiner S. et al., J Endovasc Ther. 2016 Apr;23(2):347-55.
  17. Werner M. et al., EuroIntervention. 2014 Nov;10(7):861-8.
  18. San Norberto EM. et al., Ann Vasc Surg. 2017 May;41:186-195.
  19. Teymen B. et al., Vascular. 2018 Feb;26(1):54-61.
  20. Bhatt H. et al., Cardiovasc Revasc Med. 2018 Jul;19(5 Pt A):512-515.
  21. Arena F. et al., J Vasc Med Surg. 2013:1;116.
  22. Chen Y. et al., J Vasc Surg 2014;59:384-91.

MAT-2106533 v2.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2025 Abbott. All Rights Reserved.

MAT-2001111 v8.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

YES

MAT-2305078 v1.0